U.S. pharma large copyright scrapped two experimental weight loss pills past year—a after-daily pill, lotiglipron, resulting from elevated liver enzymes plus a two times-day by day tablet, danuglipron, due to solid Unintended effects—but CEO Albert Bourla has stated the company is determined to “Engage in and earn” from the being overweight